DKSH expands Grünenthal partnership to launch pain drugs in eight Asia-Pacific markets

By Public Technologies
  • DKSH entered a regional partnership with Grünenthal to commercialize specialty pain medicines across up to eight Asia-Pacific markets.
  • Agreement covers launches of four products, including Qutenza, Palexia, Vimovo, across markets such as Singapore, Thailand, Vietnam.
  • DKSH will provide end-to-end commercialization support, spanning regulatory, market access, medical affairs, distribution, supply chain.
  • Deal expands a prior partnership that covered three established Grünenthal medicines in the region.
  • Partnership announced Sept. 28, 2026, targeting faster access to pain therapies, supporting Grünenthal portfolio growth in Asia-Pacific.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DKSH Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2405748_en) on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.